Company: REVB
Filing Date: 2025-04-04
Form Type: DRS
Source: 0001213900-25-029022
Chunk: 211

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-04-04
Form: DRS
Chunk 211
---
 F Warrants have an alternative cashless exercise provision that allows the holder thereof to receive two shares of common stock without payment of the exercise price. The Company valued the Class F Common Stock Warrants based on the alternative cashless exercise provision issued and recognized approximately $4.1 million and included in the issuance costs of the Class E Warrant Inducement and treated as equity. The Class F Common Stock Warrants are exercisable for a period of two years from January 17, 2025. In connection with the Class E Warrant Inducement to exercise the Class E Common Stock Existing Warrants, the Company issued 6,096,060 Class G Common Stock Warrants to purchase up to 381,004shares of common stock at an exercise price of $16.00 per share, valued on the Class E Warrant Inducement date in the aggregate at $2.1 million and included in the issuance costs of the Class E Warrant Inducement and treated as equity. The Class G Common Stock Warrants are exercisable for a period of five years from January 17, 2025. As part of the 2025 Reverse Stock Split on January 28, 2025, the number of shares of common stock the Class G Common Stock Warrants are exercisable into was reset from 381,004 to 1,621,463 and the exercise price of the Class G Common Stock Warrants was reset from $16.00 to $3.7596.

F-24

REVELATION BIOSCIENCES, INC. Notes to the Consolidated Financial Statements 10. Warrants (cont.) The fair value of the Class G Common Stock Warrants were estimated using the Black -Scholesoption pricing model with the following assumptions:

| Volatility              |     |  100 | % |
| Expected term (years)   |     |    5 |   |
| Risk-free interest rate |     | 4.38 | % |
| Expected dividend yield |     |  0.0 | % |

11. Income Taxes The Company did not record a provision for income taxes for the years ended December 31, 2024 and December 31, 2023 due to a full valuation allowance against its deferred tax assets. The difference between the provision for income taxes and income taxes computed using the effective U.S. federal statutory rate is as follows:

|                                                       |     |   Year Ended 
 December 31, 
         2024 |   |     |